<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Apricus Biosciences 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=15987></link><description><![CDATA[Apricus Biosciences 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Fri, 15 May 2026 23:52:59 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[Apricus Biosciences&#039; Wholly-Owned Subsidiary NexMed(U.S.A.) and Takeda Pharmaceuticals International GmbH Sign Exclusive License Agreement to Market Vitaros(R) in the United Kingdom]]></title><link>https://www.newswire.co.kr/newsRead.php?no=650509</link><description><![CDATA[SAN DIEGO and ZURICH, Switzerland--(Korea Newswire)--Apricus Biosciences, Inc. (Nasdaq:APRI) and Takeda Pharmaceuticals International GmbH jointly announced today that they have entered into an exclusive license agreement to market Vitaros®, a treatment for erectile dysfunction, in the UK.  Under the terms of the agreement, Takeda will pay NexMed (U.S.A.), a wholly owned subsidiary of Apricus Bios...]]></description><pubDate>Thu, 13 Sep 2012 19:00:00 +0900</pubDate></item><item><title><![CDATA[Apricus Biosciences Announces Korean Patent Approval for MycoVa(TM) for Nail Fungus]]></title><link>https://www.newswire.co.kr/newsRead.php?no=574004</link><description><![CDATA[SAN DIEGO--(Korea Newswire)--Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI)  announced today that the Korean Patent Office will grant a patent for MycoVa™, indicated for the treatment of onychomycosis (commonly referred to as nail fungus).  Specifically, the Korean Patent Office recently issued a “notice of allowance” for the Company's patent appli...]]></description><pubDate>Tue, 04 Oct 2011 09:33:06 +0900</pubDate></item></channel></rss>